Mineralys Therapeutics, Inc. Common Stock Asset Resilience Ratio
Mineralys Therapeutics, Inc. Common Stock asset resilience ratio. Mineralys Therapeutics, Inc. Common Stock (MLYS) has an Asset Resilience Ratio of 78.33% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See MLYS days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Mineralys Therapeutics, Inc. Common Stock (2021–2025)
Asset resilience ratio of Mineralys Therapeutics, Inc. Common Stock from 2021 to 2025. This chart shows how Mineralys Therapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. Read MLYS current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Mineralys Therapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see MLYS total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $523.14 Million | 78.33% |
| Total Liquid Assets | $523.14 Million | 78.33% |
Asset Resilience Insights
- Very High Liquidity: Mineralys Therapeutics, Inc. Common Stock maintains exceptional liquid asset reserves at 78.33% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Mineralys Therapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Mineralys Therapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Mineralys Therapeutics, Inc. Common Stock Asset Resilience Ratio by Year (2021–2025)
Mineralys Therapeutics, Inc. Common Stock asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for Mineralys Therapeutics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 73.09% | $483.71 Million | $661.81 Million | +32.25pp |
| 2024-12-31 | 40.84% | $84.10 Million | $205.90 Million | -33.58pp |
| 2023-12-31 | 74.42% | $187.26 Million | $251.64 Million | +54.84pp |
| 2022-12-31 | 19.58% | $22.41 Million | $114.44 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $11.12 Million | -- |
About Mineralys Therapeutics, Inc. Common Stock
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, an… Read more